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ABSTRACT
A PILOT STUDY OF POLYCYCLIC AROMATIC HYDROCARBONS IN
MATERNAL AND CORD BLOOD PLASMA
March 30, 2007
Polycyclic aromatic hydrocarbons (PAH) are chemicals generated from
the incomplete combustion of organic materials, including tobacco smoke. Some
PAH are known to be mutagenic and carcinogenic in humans, and of concern for
the fetus when women smoke during pregnancy. Known consequences of
smoking during pregnancy include low birth weight and preterm delivery. It is
unknown if PAH are related to these outcomes. This pilot study was designed to
measure concentrations of 3 PAH (anthracene, benzo(a)pyrene and 1hydroxypyrene) in paired maternal and cord blood samples as well as any
correlations between the two matrices. Plasma cotinine was used as a
biomarker of tobacco exposure. Additionally, we asked if there is any
relationship between the PAH concentrations and low birth weight or preterm
delivery.
Results showed that all 3 PAH could be found in maternal and cord
plasma. Anthracene was consistently shown to be significantly elevated in cord
plasma compared to maternal plasma in subgroups based on increasing cotinine
concentrations. However, none of the compounds studied were correlated with
either birth weight or gestational age.
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INTRODUCTION
Environmental pollution has been around since the dawn of life on earth.
Human-generated environmental pollution has been around at least since the
discovery of fire in the Paleolithic Period. The advances and discoveries of
civilization (the Renaissance, the Industrial Revolution, fossil fuels, the
automobile, atomic energy, etc.) have increased the rate at which humangenerated pollution has affected the health of the planet (air, water, soil) and the
species that inhabit it. Environmental pollution is known to cause or contribute to
a number of human diseases, including cancer, developmental disorders and
immune, cardiovascular and pulmonary diseases. Among the many compounds
that contribute to environmental pollution are the polycyclic aromatic
hydrocarbons, a group of compounds with potential for carcinogenic and
mutagenic activity in humans.
Polycyclic aromatic hydrocarbons (PAH) are products of incomplete
combustion of organic matter. They are made up of fused benzenoid rings as
well as unsaturated 4-, 5-, and 6-membered rings. Sources include automobile
exhaust, coal-fired energy plants, tobacco and wood smoke, as well as
grilled/smoked foods. (1) PAHs are highly lipid-soluble, readily absorbed from
the gastrointestinal tract and rapidly distributed throughout the body, especially
into fat tissue. (2) Metabolism occurs via the cytochrome P450-mediated mixedfunction oxidase system, yielding, among other things, highly reactive epoxides
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that are known to be carcinogenic, mutagenic and/or developmentally toxic. (3, 4)
In studying the effects of PAH exposure, benzo[a]pyrene is widely used as a
“representative PAH” because, at least in the urban setting, concentrations of
individual PAHs are highly correlated. In addition to its carcinogenic potential,
benzo(a)pyrene has also been shown to act as an endocrine disruptor due to its
structural similarity to the cholesterol core of many hormones and/or by
interfering with hormonal activity (5). Among other PAH compounds, 1hydroxypyrene has often been followed in urine as a marker of PAH exposure.
Anthracene, while not carcinogenic itself, has the potential for easy methylation
at the 9- and 10- carbons on the middle ring to much more toxic compounds that
are indeed carcinogenic (9-methyl anthracene and 10-methyl anthracene).
One common source of polycyclic aromatic hydrocarbons is tobacco
smoke. It is ubiquitous in the environment and its use is recognized as
detrimental to human health. It is especially problematic during pregnancy when
the fetus is at great risk for significant harm from the chemicals that will cross the
placenta and influence subsequent development. This study will focus on the
presence of 3 specific PAH among the many compounds in tobacco smoke in
maternal and cord blood (see Figure 1).
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Figure 1.
Chemical structures of polycyclic aromatic hydrocarbons of interest in this
study.

Benzo(a)pyrene

1-hydroxypyrene

Anthracene

BACKGROUND

Concerns about atmospheric contamination are not new. Thirteenth
century England was blanketed in coal smoke as Londoners switched from
burning wood for fuel (as wood became scarce and expensive) to heating with
sea-coal, a relatively plentiful (and cheap) but dirty alternative fuel. Such practice
was banned by royal edict as far back as 1272, but citizens were not deterred.
The term “smog” was coined in the early 1900s to describe the air of London,
where naturally occurring fog combined with coal-burning smoke to envelope the
city and surrounding areas. (6)
The early to mid-20th century saw a number of air stagnation events
(periods of extraordinarily heavy pollution) that resulted in excess deaths and
hospitalizations among citizens in the United States and elsewhere. (7, 8) These
events provided well-defined intervals in which specific data (atmospheric
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conditions, hospital admissions and deaths) could be analyzed by scientists and
governmental officials in order to better understand the short term effects of
ambient outdoor air quality on public health. Epidemiological studies showed
generally that the combination of increased concentrations of smoke and sulfur
dioxide in the air, along with a given individual’s underlying biophysiological
susceptibility (primarily cardiovascular or pulmonary disease), resulted in
morbidity and mortality rates up to 10-fold higher than normal. (7)
Environmental pollution also contributes to respiratory hypersensitization,
which has been on the increase in Western nations over the past several years.
Allergic diseases are the 6th leading cause of chronic illness in the U.S., affecting
up to 17% of the population and costing $18 billion annually. (9) Particulates,
including soot, pollen, animal dander, insects and microbes, can trigger tissue
inflammation/injury and airway reactivity (rhinitis, asthma, chronic bronchitis,
etc.). (10, 11) Infants and children are especially sensitive to particulate pollution.
Despite the fact that such chronic illnesses are not generally fatal (and
consequently not reflected in mortality data), the social impact in terms of
hospital admissions, missed school/work days, etc. is still significant. Studies
from the Centers for Disease Control and Prevention have shown that up to 40
million Americans have chronic allergic rhinitis (hay fever) related to common airborne allergens, resulting in approximately 3.8 million lost days of work and
school annually (12).
Although overall air quality in the late 20th and early 21st centuries is much
improved over that in the 1950s and 1960s, indoor air pollution remains a
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significant contributing factor to morbidity and mortality. The most ubiquitous
indoor pollutant is tobacco smoke, which is known to contain over 4,000
chemicals (including PAHs) and has been classified as a carcinogen by the
United States Environmental Protection Agency. Environmental tobacco smoke
is made up of both mainstream smoke (that which has been inhaled by the
smoker and then exhaled) and side-stream smoke (that emitted directly from a
burning cigarette). Sidestream smoke is considered to be more toxic, gram for
gram, than mainstream smoke since it contains chemicals and particulates in
higher concentrations than smoke that has been scrubbed (filtered) by the
smoker’s lungs. (13) Involuntary or passive smoking (a combination of
mainstream and side stream smoke) by individuals sharing significant amounts of
time and space with active smokers has been shown to increase the risk of
serious lung disease (asthma, chronic bronchitis) as well as lung cancer. (14)
The developing fetus is the most vulnerable of involuntary smokers.
Studies in reproductive epidemiology have shown that fetuses and infants are
more likely to have a heightened sensitivity to any number of environmental
toxicants due to their degree of exposure in relation to organ mass, physiologic
immaturity to detoxify such compounds and critical windows of growth and
development that may be negatively impacted by such exposures. (15-18)
Convincing evidence already exists that relates maternal smoking during
pregnancy with low birth weight (LBW, weight under 2.5 kg), intrauterine growth
restriction (IUGR, weight for gestation less than 10th percentile), placenta previa
(attachment of the placenta in the lower part of the uterus, often resulting in
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excessive bleeding), placental abruption (precipitous detachment of the placenta
from the uterus before birth of the infant), miscarriage and preterm delivery. (1941) Life-long risk for postnatal or adult-onset disease in the infant whose mother
smoked during pregnancy has not, so far, been quantified, primarily due to
multiple family, socioeconomic and environmental confounding factors. However,
measurable evidence of genetic damage from environmental tobacco smoke in
non-smokers is mounting. (42-46)
Using paired maternal-cord blood specimens, this study will address the
following research questions:
1. Are anthracene, benzo(a)pyrene and 1-hydroxypyrene present in
measurable concentrations in maternal and cord blood plasma?
2. Do plasma concentrations of anthracene, benzo(a)pyrene and/or 1hydroxypyrene correlate with cotinine among smoking and non-smoking
women?
3. Do plasma concentrations of anthracene, benzo(a)pyrene and/or 1hydroxypyrene in cord blood parallel levels in maternal plasma?
4. Are plasma concentrations of anthracene, benzo(a)pyrene and/or 1hydroxypyrene correlated with birth weight or gestational age?

GENERAL ENVIRONMENTAL CONCERNS
Air pollution is a public health issue with political/social underpinnings. A
number of epidemiological studies have shown associations between
morbidity/mortality rates and air quality all across the globe. (1, 5, 7, 11, 16, 17,
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47-55) This research has examined risks in urban vs. rural communities, white
collar vs. blue collar neighborhoods, indoor vs. outdoor pollution, industrialized
vs. developing countries and across all age groups. There is little question that
the general health of any community is highly dependent on the quality of the air
its citizens breathe. However, one of the challenges of interpreting
epidemiological studies is to quantify and control for the effects of multiple
cofactors (social, cultural, economic). Public policy must be a driving force for
pollution abatement, as pollution is a product of the activities of individuals,
industries and governments, all of which must be balanced for the good of the
community.
An increasing prevalence of asthma/respiratory hypersentization has been
noted across the globe in recent years. Bascom (10) reviewed a number of
studies from North and South America supporting the hypothesis that
environmental factors contribute to the development of respiratory allergy,
asthma, and chronic bronchitis. In addition to the usual triggers (pollen, dust
mites, animal dander) the author discusses how ambient air pollutants (fossil fuel
emissions, particulates, etc., both stationery and mobile) and unfavorable climatic
conditions can compound the allergic response in individuals that have a genetic
susceptibility to this heightened sensitivity. While “air pollution” is often used to
imply a singular entity, it is actually variable in character depending on the
sources, the climate, the season, and the chemicals in the mix. Human
responses to elevations in specific pollutants can range from cough and
shortness of breath to asthma exacerbation, lung injury and decreased lung
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function. (56) Ozone, a secondary atmospheric pollutant formed by the
photochemical reaction between nitrogen oxides and hydrocarbons, is often
increased in summer months when fossil fuel emissions react with sunlight.
Exercising in an elevated ozone environment can lead to decreased lung
function, tissue injury and inflammation, all of which are measurable for hours
after exposure ceases. Epidemiologic studies show that such conditions are
associated with increased hospitalizations and emergency department visits for
individuals with respiratory risk factors. (56)
Particulate matter (PM) has been shown increasingly in recent years to be
an important factor in defining air quality, due to effects on heart and lung health.
PM is a complex mixture of small particles and liquid droplets, with particle size
directly linked to potential for negative health effects. (57) Particulates that are
10 micrometers (microns, µ) or smaller are of the strongest concern because
they are generally not filtered out by the upper airway (nose and throat), and
pass on into the lungs. Coarse particles, 2.5 – 10 µ in diameter) are often
detected in dusty areas/regions and near industrial sites. Fine particles, 2.5 µ or
smaller) are common components of smoke and haze and found in the
emissions of power plants, industries and auto exhaust.
Dockery et al conducted a prospective, cohort study of air pollution and
mortality among adults in 6 United States cities from 1974-1991. (48) At the time
of enrollment, subjects underwent baseline spirometric testing and completed
questionnaires detailing medical and smoking history, as well as occupational
exposures. During the intervening years, subjects were contacted annually for
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updates on medical and vital status. Ambient air quality data were obtained from
governmental sources. Death certificates were obtained for 98% of those who
died during the study period; causes of death were independently verified. After
adjusting for smoking behavior and other risk factors, there remained a
statistically significant association between air pollution (especially fine
particulates) and mortality (adjusted rate ratio 1.26 (95% C.I. 1.08-1.47).
Epidemiological studies from South Korea, (51) Czechoslovakia (47) Mexico (53)
and California (58) have shown that even among infants, after controlling for
premature birth and underlying respiratory disease (e.g. bronchopulmonary
dysplasia), there is credible evidence that fine particulate matter (PM2.5 ) air
pollution contributes to respiratory-related deaths in the post-neonatal period.
In the Louisville, KY region of the Ohio Valley, air pollution control is a
constant battle, especially in the summer months when heat, humidity and
stagnant weather patterns exacerbate baseline pollution conditions. While air
quality is much improved over the mid- late- 20th century, the region still saw 8
days of excessive ozone (U.S. Environmental Protection Agency standard > 85
parts per billion for 8 hours), in the year 2005. (59) In terms of PM2.5, a more
recently implemented pollution control measure, the Louisville Metro area
continues to struggle with significant elevations, primarily in the summer months.
In each year from 1999-2005, concentrations of PM2.5 exceeded the acceptable
standard (15 µg/meter3) in the months of June, July and August from 1.1-2.0 fold.
(60) Reports from the first 5 months of 2006 showed that PM2.5 pollution was
significantly down from previous years and met/exceeded the national standard.

9

Data from the summer months of 2006 were not available at the time of this
paper.
Environmental pollutants can also impact the orderly development of
organisms as well as normal cellular processes. Pesticides, (61-63) radiation,
(64, 65) and heavy metal compounds (17, 66-68), whether in the water, soil or
air, all have the potential to cause disruptions in the normal maturational
sequence. During embryogenesis and even beyond, the presence (or absence)
of chemical signals can permanently alter the structure and function of cells,
tissues and organs. Slotkin et al have shown the disruptive effect of nicotine, a
neurologically active chemical with specific receptors, on the developing brain in
a rat model. (69) When a pregnant rat was exposed to an infusion of nicotine
comparable to that found in (human) heavy smokers, there were 4 major
neurological effects in the post-natal rat pup, including presence of markers of
cell damage, decreased numbers of cells, inhibition of DNA synthesis and
blunted synaptic activity in the forebrain. These effects indicate that, at least in
the rat, nicotine, one of many chemicals humans acquire primarily through
cigarette smoking, is a nervous system teratogen associated with significant
short and long-term alterations in normal brain development.
In the human brain, nicotine reacts with nicotinic acetylcholine receptors,
(70) which appear as early as 4-5 weeks’ gestation. As in the rat model, these
receptors are involved in modulating dendritic outgrowth, establishment of
neuronal connections and synaptogenesis during development. (71) In the
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immature brain, stimulation of these receptors leads to interaction with the genes
that control cell replication, differentiation, growth and death. (72)
Epidemiological studies have suggested that in-utero exposure to nicotine
is associated with negative neurobehavioral effects later in childhood and
adolescence. (73-76) However, the confounding effect of socioeconomic factors
on childhood behavior have made direct linkage between smoking and later
behavior difficult to interpret. Recently, Maughan et al, using the Longitudinal
Twin Study of Britain, showed that prenatal smoking had a strong and statistically
significant dose-response relationship to childhood conduct disorders at 5 and 7
years of age, especially in boys. (77) The researchers found that approximately
two-thirds of the variation in the reported conduct problems at each age was
found to be attributable to genetic factors. However, after controlling for the
genetic influences, prenatal smoking in the mother continued to predict such
problems. In an effort to account for more potentially confounding factors, the
researchers measured social-environmental factors that may have contributed to
the observed behaviors. Once parental antisocial behavior, maternal depression
and social deprivation were controlled in the analysis, in addition to the genetic
risk, the strong initial effect of smoking on early childhood conduct was reduced
by about 75%. For children of women that were light-moderate smokers, the
effect was non-significant. For children of women that were heavy smokers, the
effects could still be detected, but the magnitude was greatly reduced.
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SMOKING EFFECTS AND CONCERNS
Among adults in the U.S., tobacco smoke has been officially linked to
cancer and cardiovascular disease in active smokers since the first Surgeon
General’s Report on Smoking and Health in 1964. (78) This report summarized
the results of more than 7,000 published articles that correlated smoking with
specific diseases. Since 1964, there have been 28 additional supplements and
reports from the Office of the Surgeon General that further describe the health
risks from exposure to environmental tobacco smoke. Other scientists from the
fields of medicine and public and environmental health continue to report on the
dangers of environmental tobacco smoke to users and those who share common
breathing space. Recently (June 2006), the current Surgeon General, Richard H.
Carmona, issued a comprehensive scientific report that concludes “there is no
risk-free level of exposure to secondhand smoke.” (14)
As noted in Table 1, adapted from “Cigarette Secrets,”(79) tobacco smoke
contains a broad array of chemicals from multiple classes that are present in both
mainstream and side stream smoke. All of those listed are considered by the
International Agency for Research on Cancer (IARC, a part of the World Health
Organization) to have sufficient scientific evidence of carcinogenicity or
tumorigenesis in animals. Those with “sufficient” evidence of carcinogenicity in
humans are noted with an S. Those with “limited” evidence are noted with an L.
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Table 1.
A partial list of toxic and carcinogenic compounds in tobacco and tobacco
smoke. (79)
Polycyclic Aromatic Hydrocarbons

Aldehydes

Benz[a]anthracene

Formaldehyde

Benzo[b]fluoranthene

Acetaldehyde

Benzo(a)pyreneS

Miscellaneous inorganics:

Chrysene

ArsenicS

Di-benzo(a,h)anthracene

CadmiumL

N-Nitrosamines

ChromiumS

N-Nitrosodimethylamine

Lead

N-nitrosoethylmethylamine

NickelL

N-nitrosonornicotine

Polonium 210S
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Tobacco smoke is one of the most ubiquitous indoor air pollutants. In
addition to the chemicals and carcinogens known to be contained in tobacco
smoke, it also contains significant amounts of particulates, including small,
respirable ones (PM2.5). (80, 81) By virtue of the differences in respiratory rate
and minute ventilation between infants and adults, infants and toddlers inhale a
larger dose of air pollutants per unit of body mass than adults breathing the same
air; they also appear to be more vulnerable to the effects. Using data from the
Third National Health and Nutrition Examination Survey (1988-1994), Gergen et
al (58) reported that respiratory complications from exposure to environmental
tobacco smoke (asthma, chronic bronchitis, and wheezing) were more common
in children 2-20 months than in children 3-5 years of age. After adjusting for
relevant confounding factors, the authors determined that the excess attributable
risk for these respiratory complications showed that 40-60% of the cases could
be linked to environmental tobacco exposure.
A causal association between involuntary smoking (passive tobacco
smoke exposure) and lung cancer appears to exist, as the risk among nonsmoking spouses has been shown to be increased 20-30% over non-smokers in
general. (13, 82, 83) In the United States, a meta-analysis of 11 epidemiological
studies showed that environmental tobacco smoke may be responsible for as
many as 3,000 lung cancers annually in non-smokers (35 and over) and up to
35,000 deaths. (13) Studies have shown that adults exposed passively to
tobacco smoke in the workplace often develop respiratory symptoms such as
wheezing, cough, etc. However, it is unclear if, or to what extent, this exposure
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explains chronic obstructive pulmonary disease or cardiovascular disease in nonsmokers.
In Kentucky, where tobacco has been a prominent cash crop throughout
the Commonwealth’s history, over 8,000 citizens die of tobacco-related diseases
each year. In 2005, Medicare and Medicaid costs related to the health effects of
tobacco were estimated to be $1.2 billion, or $300/Kentuckian. (84) Kentucky
exceeds the national average in prevalence of tobacco use in all age categories
(adult, high school and middle school), racial/ethnic groups (whites, AfricanAmericans), gender and during pregnancy. By far, annual deaths from cancers of
the trachea, lung and bronchus are the leading causes of smoking-attributable
mortality (SAM).
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Table 2.
Comparisons of tobacco use and consequences in Kentucky and in the
U.S. (84, 85)
Kentucky

U.S.

Any tobacco (%)

28

21

Males (%)

29

23

Females (%)

26

19

Caucasians (%)

29

22

African-Americans (%)

30

20

Hispanics (%)

16

15

Middle school (%)

24

13

High school (%)

44

28

During pregnancy (%)

24

11

5,597

3,805

385

273

Years of potential life lost (per 100,000 persons)
Smoking Attributable Mortality (per 100,000 persons)

SMOKING CONCERNS AMONG MOTHERS AND INFANTS
For infants and children, it has been shown that living in homes with
tobacco smoke clearly results in more coughing, wheezing and respiratory illness
than living in smoke-free homes. (13, 58) In the United States, it is estimated that
35-40% of children live in homes where others smoke. (86) Diagnoses of
asthma, chronic bronchitis and wheezing increase with increasing environmental
tobacco smoke exposure and with decreasing postnatal age. (58)
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Among women of childbearing age, the negative effects of environmental
tobacco smoke can reach beyond personal health risks to those of a developing
fetus. Multiple studies have addressed the consequences of maternal smoking
during pregnancy both for the mother and the infant: increased risk for premature
rupture of membranes, (87, 88) premature birth and low birth weight (birth weight
<2.5 kg), (89-91) placenta previa/abruption, (92) miscarriage, and stillbirth. (93,
94)
The link between smoking during pregnancy and LBW was first reported
by Simpson in 1957 (35) and has been confirmed in numerous reports since.
This effect is independent of other factors that influence birth weight, including
gestational age, gender, parity, race, pre-pregnancy anthropometrics, and
socioeconomic status. A series of 14 studies from the United States, Canada,
the United Kingdom, Italy, Norway and Sweden during the years 1959-91 were
compared in the 2001 Surgeon General’s Report on Women and Smoking. (36)
Smoking intensity was defined by either maternal report or cotinine
concentrations. Infants of smokers were 66-320 grams lighter at birth when
compared to infants of non-smokers. In general, the more a woman smoked, the
larger the birth weight deficit when compared to the infant of a non-smoker.
The primary mechanism of reduced fetal growth due to smoking is
presumed to be a combination of relative hypoxia due to placental
vasoconstriction and carbon monoxide binding to fetal hemoglobin oxygen.(9597) However, it is possible that other mechanisms, including altered nutrient
metabolism, contribute as well. (98-101) Studies by D’Souza et al (26) and
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Harrison et al (102) showed that the reduction in birth weight was related to loss
of lean mass rather than reduced fat deposition, which is consistent with an
hypoxic or other non-nutritional mechanism. Smoking during the first trimester of
pregnancy is temporal with cellular hyperplasia and organogenesis. Any of these
mechanisms may function to alter or restrict the normal developmental pattern or
influence a critical window that cannot be recovered.
Smoking cessation during pregnancy can lead to gains in birth weight and
reductions in the likelihood of low birth weight. Secker-Walker et al conducted
clinical trials examining smoking cessation and relapse prevention. (103) They
ascertained cigarette consumption by both maternal report and urinary cotinine
levels and found that women who stopped smoking early in pregnancy (before
the first prenatal visit) and remained abstinent could reduce the expected birth
weight loss by as much as 300 grams.
England and colleagues compared the effects of 3 different patterns of
cigarette exposure during pregnancy (quit, reduced, increased) with women
whose smoking behavior did not change. (104) Patterns were determined by
personal report and urinary cotinine measurements. Women that reduced/quit
smoking before or soon after study enrollment delivered infants that were, on
average, ~32 grams heavier than babies of women that continued the same level
of smoking. However, when birth weight was stratified by maternal cigarette use
at enrollment, infants of women with low exposure who then reduced their
cigarette consumption were ~200 grams heavier than infants of women who were
light, but consistent, smokers.
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In Kentucky, the incidence of low birth weight has been higher than the
national average for the past decade. This is accompanied by a high prevalence
of smoking during pregnancy, with rates in Kentucky usually the highest in the
nation.
Table 3.
Prevalence of low birth weight (% live births) and smoking during
pregnancy in the United States and Kentucky in 3 time periods. (105)
1995-1997

1998-2000

%

2001-2003

%

%

% LBW

Smokers

% LBW

Smokers

% LBW

Smokers

Kentucky

7.8

24.5

8.2

24.5

8.6

24.4

U.S.

7.4

13.6

7.6

12.6

7.8

11.4

Specific studies have addressed the effects of smoking on indices of
newborn health. Symptoms of neonatal nicotine withdrawal, including jitteriness
and irritability, have been described by multiple authors. (106-109) Alterations in
body composition and growth have been known and studied for decades. (23,
92, 110-113) Evidence suggests that there is a dose-response as well as a
temporal relationship between smoking and reduced birth weight. (22, 28, 104,
114-116) The earlier in her pregnancy a woman quits, the smaller the effect on
her infant’s birth weight. (104, 117) Smoking also is associated with lower levels
of markers of bone metabolism in infants of smoking mothers when compared to
those of women that do not smoke. (118-121) The biological explanations for
these effects have centered on immunologic (100) as well as physiologic
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pathways. (122) Postnatally, an increased risk for Sudden Infant Death
Syndrome (SIDS), (123, 124) upper respiratory tract infection, and asthma has
been linked to smoking by adults in the child’s environment (58, 125, 126).
According to the Centers for Disease Control and Prevention (CDC), the
prevalence of smoking during pregnancy in the United States in 2002 was
estimated to be 11.4%, a decrease of 38% from 1990. (127) During that same
12-year period, the rate in Kentucky decreased only 14.4% to 24.4%, a rate
exceeded only by pregnant women in West Virginia (26.2%). Among females
aged 15-19, the rate of smoking during pregnancy in Kentucky increased from
32.9% to 34.1% (1990-2002). Only Vermont, New Hampshire and West Virginia
had teen rates that were higher during that period. Figure 2 shows that the 24%
overall rate for Kentucky, while alarming in an of itself, does not convey that there
are regions of extremely high tobacco use in certain parts of the Commonwealth
where the prevalence is 3-4 times that across the United States. Coupled with
the increased rates of prematurity and low birth weight, the financial burden on
Kentuckians related to smoking during pregnancy is significant. CDC analysis of
data from pregnancy risk surveillance and birth certificates resulted in an
estimate of smoking-attributable neonatal expenditures (in 1996 US dollars) of
$704 per maternal smoker (range $519-1,334) both nationally and in Kentucky.
(128)
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Figure 2.
Prevalence of smoking during pregnancy in Kentucky by county. (84)

21

The impact of personal cigarette smoking in the short term (pregnancy
and the neonatal period) on the health of mothers and infants has been
discussed. However, passive exposure to tobacco smoke at home or in the work
place can also be detrimental to a woman and her infant during pregnancy and
postnatally. Side stream smoke represents approximately 85% of total
environmental tobacco smoke and contains higher concentrations of some
carcinogens than does mainstream smoke. (13) Outcome studies comparing
birth weight of infants of pregnant non-smokers passively exposed to tobacco
smoke to infants of non-exposed women have had varied results. Generally,
though, they show that the birth weight reduction in infants of passively exposed
women was smaller than that seen in infants of active smokers. (38, 129) Horne
et al. and others have reported that infants exposed pre- and post-natally to
tobacco smoke have decreased arousability from sleep, (130-133) which may be
a contributing factor to sudden infant death syndrome (SIDS). Although the
specific cause of SIDS remains elusive, since the introduction of the “Back to
Sleep” program in the early 1990’s, deaths from SIDS have declined by almost
50%, leaving exposure to environmental tobacco smoke as one of the strongest
remaining (and modifiable) risk factors for this event. (134) Infants and children
chronically exposed to tobacco smoke in the home also have a significantly
increased risk of developing asthma, allergies and upper respiratory infections
(bronchitis, ear infections, pneumonia). (58, 135-137).
Tobacco smoke is a toxicant to the embryonic, fetal and postnatal lung
and can exert varying degrees of harm throughout gestation and beyond, based
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on the stage of lung development (proliferation, differentiation, branching) at the
time of the exposure. (17) Enzyme systems necessary for intrapulmonary
metabolism as well as the detoxification of foreign molecules (epoxide hydrolase,
cytochrome P450 mono-oxygenases, glutathione-S-transferase, and other antioxidant systems) mature at differing rates throughout gestation and after birth.
Exposure to damaging compounds prior to the availability of these enzymes may
permanently alter their developmental profile. Molecular signals orchestrate the
process temporally and spatially throughout the continuum from embryogenesis
through adolescence, when lung growth is generally complete. Substances that
interfere with these signals may result in deviant lung development. Although a
normal term pregnancy (40±2 weeks) allows for development that is adequate to
sustain life, fully 80% of lung development occurs after birth. (17) Continued
exposure to pollutants such as tobacco smoke perpetuates the risk for altered
development.
Nicotine (a component of the tobacco leaf and tobacco smoke) is readily
transported to the fetal compartment via the placenta. (15) Luck et al. showed
that the serum nicotine ratio (umbilical vein/maternal) was 1.12±0.3, evidence
that it is concentrated in the fetus compared to the mother. (138) The authors
also found that nicotine in the amniotic fluid was increased up to 88% relative to
maternal serum values. Nicotine’s effects include decreased uterine artery blood
flow, variable changes in umbilical artery flow, changes in fetal oxygenation (due
to the binding of carbon monoxide to fetal hemoglobin) and acid base balance,
as well as decreased fetal heart rate and increased mean arterial pressure.
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(139). Nicotine has been shown to be toxic in adults with doses as small as 2
mg. (140)
Amniotic fluid, which bathes, nourishes and cushions the fetus during
gestation, actually represents fetal urine. During the first trimester of pregnancy,
it is derived from maternal blood plasma that diffuses through the tissues of the
fetus into the surrounding fluid. From approximately 10-11 weeks (simultaneous
with the formation of fetal kidneys), the major component of amniotic fluid is fetal
urine, supplemented with growth factors and secretions from the lungs, oral and
nasal cavities, as well as the fetal surface of the placenta. This fluid is constantly
circulated as the baby "inhales" (swallows) existing fluid and replaces it through
"exhalation" (urination). The fetal skin is highly permeable prior to keratinization
(about mid-gestation) and readily absorbs compounds present in the surrounding
fluid. Thus, from around 10 weeks of gestation, the fetus of a smoking mother is
chronically exposed to tobacco products by multiple routes: maternal circulation,
placental transport, dermal and gastrointestinal absorption. (141, 142)
Cotinine is the major metabolite of nicotine and it has been used for a
number of years as a biomarker of exposure to cigarette smoke due to its
chemical stability, persistence in the blood stream (half-life ~24 hours) and
freedom from interfering substances. Jauniaux et al detected cotinine in fetal
fluids as early as 7 weeks’ gestation. (141) Donnenfeld et al measured
simultaneous serum cotinine concentrations in a small number of maternal/fetal
pairs undergoing clinically-indicated percutaneous umbilical blood sampling
between 21 and 36 weeks gestation, (143) finding a mean fetal/maternal cotinine
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ratio of 0.9 (95% CI 0.83-0.97). Eliopoulos et al measured nicotine and cotinine
in hair of newborn infants, finding a dose response based on maternal smoking
behavior and a linear relationship between cotinine levels in individual mothers
and babies. (144) It is not clear if the cotinine measured in fetal tissues/fluids is
the product of fetal metabolism of maternal nicotine or if it is maternal cotinine
passed to the fetus via the placenta. (143)
In pregnancy, the placenta is the organ of exchange between the fetal and
maternal circulations. It is made of fetal (chorionic) and maternal (endometrial)
components and serves to provide nutrition, respiration and excretion for the
fetus. These functions are carried out through metabolic, transfer, endocrine and
immunologic activities. Compounds that enter the mother’s body (nutrients,
medications, toxins, etc.) may travel directly to the fetus or may be modulated by
maternal metabolism or placental activity. While the human placenta can
metabolize many foreign chemical compounds, the breadth of metabolizing
enzymes is more limited than in the liver which is the primary detoxifying organ.
Hakkola et al showed that there may be a gestational influence on the
appearance and duration of effect of some of the cytochrome-P (CYP) family
enzymes. (145, 146) Their studies revealed that mRNA for several CYP enzymes
was present in human placental tissue as early as the first trimester, when mitotic
frequency is high and there is rapid functional and structural development. They
also showed that the number of different mRNAs that were detectable decreased
as the pregnancy reached term. The presence of toxic substances, such as
PAH, in placental tissues or fluids during critical windows of development is
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alarming in view of the high rates of hyperplasia and hypertrophy in the placenta
and the fetus and the potential for disruption of normal maturational processes.
PAH are known to cross the placenta, although animal experiments have
indicated that the fetal dose is probably an order of magnitude less than that
presented to maternal organs and tissues. (147-149) Yet, further animal studies
have shown PAH administration/exposure in the pregnant female can lead to
tumor development in the offspring in a multitude of organ systems, including
liver, lung, lymphatics and central nervous system (150-152).
The presence of PAH compounds in placental tissues from both smoking
and non-smoking women has been demonstrated by Gladen et al (153).
Placentae were drawn from births in two Ukrainian cities participating in the
European Longitudinal Study of Pregnancy and Childhood (ELSPAC) a program
of the World Health Organization. The Ukraine ELSPAC study was conducted by
the Ukrainian Institute of Pediatrics, Obstetrics and Gynecology in cooperation
with the University of Illinois School of Public Health. The cities were known to
have a history of significant industrial air pollution problems. Smoking status of
the mothers was determined by questionnaire at 20 weeks gestation. Seven
specific PAH were measured (including anthracene and benzo(a)pyrene). Levels
were generally higher in smokers when compared to non-smokers. However, of
178 samples analyzed, only 8 (4.5%) were from women that admitted to being
current smokers; 21% classified themselves as ex-smokers.
Madhavan et al (154) reported the presence of benzo(a)pyrene,
dibenzo(a, c)anthracene and chrysene in maternal blood, cord blood, breast milk
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and placental tissue from non-smoking Indian women. Except for
benzo(a)pyrene, the other PAH compounds were higher in concentration in cord
blood than other matrices; benzo(a)pyrene was highest in maternal milk. The
authors believed the primary source to be grilled/fried foods common in the diet
in that population. The lipophilic nature of PAH helps to explain the elevated
concentrations in human milk but also reveals human milk to be a significant
source of exposure for the breast-feeding infant.

PROGRAMMING IN-UTERO AND CHRONIC DISEASE IN ADULTS
By definition, an embryo, later a fetus, is expected to spend approximately
280 days in a developmental continuum: hyperplasia and hypertrophy, cellular
replication and organ maturation. Periods of extreme cellular activity may
justifiably be called critical windows in which the absence of an essential factor or
the presence of a noxious substance may result in altered development. Strong
evidence exists that environmental exposures of various kinds during pregnancy
can have profound effects that may predispose an infant to vulnerabilities in the
postnatal period and beyond, (155) a concept that has been termed
“programming” by some researchers.
The theory of “programming” is based on the hypothesis that in-utero or
early childhood events/exposures that occur at sensitive or critical periods of
development may alter the structure, physiology and/or metabolism of an
individual for a lifetime. (156) Barker and others have written extensively about
the evidence for this theory and have shown that the risk for a number of adult,
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chronic diseases can be associated with sub-normal size at birth (low birth
weight). (156-159) The list of candidate diseases includes coronary artery
disease (CAD), (160-162) insulin resistance/type II diabetes, (163-165)
hypertension, (22, 166, 167) and obesity. (168) The exact mechanism for
expression of in-utero events decades after they occurred is not known, but
speculation has centered on altered programming of the hypothalamic-pituitary
adrenal axis (169, 170) which may manifest as alterations in secretion of cortisol
(171, 172) and/or insulin-like growth factor. (173) Whether the alteration in
cortisol is an increase (171, 172) or a decrease (174-176) is unclear. What is
intriguing is that thinness at birth, coupled with an increased “tempo of growth” in
childhood appears to translate into an increased risk for heart disease in later
adulthood. (161) The classic outcome in infants of mothers that smoke is lower
birth weight than in infants of women that do not smoke. Is there any reason to
believe that the high prevalence of such adult morbidities as coronary artery
disease, diabetes and obesity in Kentucky can be linked, at least to some
degree, with the historic pattern of maternal smoking during pregnancy?
This pilot study was designed to investigate the presence of 3 specific
PAH, all with carcinogenic/mutagenic potential, in maternal-cord blood
specimens from women living in the Jefferson County Kentucky region. An
additional objective was to determine if there was any relationship between those
PAH and birth weight or gestational age.
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MATERIALS AND METHODS
This study was approved by the University of Louisville Institutional
Review Board and the Norton Hospital Research Office prior to initiation.
Blood samples were collected at Norton Hospital, an urban delivery center
in Louisville, KY. The maternal population has been shown in past studies to be
comprised of 30-40% smokers (from light to heavy) as well as multiple
ethnicities. Anonymous paired specimens (maternal and cord) were drawn by the
labor and delivery staff into tubes containing the anti-coagulant lithium heparin.
Maternal specimens were drawn with other ordered labs at the time of admission.
Cord blood specimens were drawn at the time of delivery. Tubes were identified
only by an ID code, M (maternal) or C (cord), with birth weight (BW) and
estimated gestational age (GA) provided on the label. Tubes were refrigerated at
4-8°C in the hospital blood bank and retrieved within 24-72 hours of collection.
Tubes were centrifuged for 15 minutes at 3500 rpm to separate plasma
from packed cells. Plasma was aliquoted into low temperature freezer tubes,
labeled with the code number and then stored frozen ( -75°C) in the Neonatal
Research Laboratory until analyzed. Packed red cells were stored separately in
the original tube for other analyses. Plasma was thawed at room temperature
and sonicated for 5 minutes prior to analysis.
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BIOCHEMICAL ANALYSIS
Reference standards were obtained from Dr. Steven R. Myers in the
Department of Pharmacology and Toxicology at the University of Louisville
School of Medicine. Stock solutions of anthracene, 3,4,8,9,-dibenzo(a)pyrene
and 1-hydroxypyrene were prepared in HPLC-grade dichloromethane (Burdick
Jackson)

.

Chromatography was performed with a Waters High Pressure Liquid
Chromatography system (HPLC) consisting of an M600E delivery system, M717
autosampler, M996 photodiode array detector (PDA) all of which were controlled
by Waters Empower Build 1154 software (version 5.00.00.00) running on a Dell
Dimension 8100 computer with Windows XP Professional operating system. The
analytical column was a 25 cm x 10 mm C18 (Waters) packed with Ultrasphere
ODS (5µ pore size). The carrier solvent was 100% acetonitrile (Burdick Jackson
HPLC grade) running isocratically at 1 mL/minute. The injection volume was 10
µL. PDA detection was full spectrum (190-600 nm) with resolution of 1.2 nm.
Each standard was run in multiple dilutions to establish linear reference curves
for each compound. See figures 3-5.
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Figure 3.
Standard curve of anthracene. Waters HPLC System with Photodiode
Array detection 190-600 nm.
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Figure 4.
Standard curve of benzo(a)pyrene. Waters HPLC System with Photodiode
Array detection 190-600 nm.
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Figure 5.
Standard curve of 1-hydroxypyrene. Waters HPLC System with photodiode
array detection 190-600 nm.
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Chromatograms for each compound were extracted at 254 nm prior to
integration which was performed with the same Waters software, using individual
PAH standard curves as references (see figure 6).
Figure 6.
Chromatogram of anthracene, 1-hydroxypyrene and benzo(a)pyrene.
Waters HPLC System with photodiode array detection, extracted at 254 nm.
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Plasma (~500 µl) was pipetted into 13x100 mm borosilicate tubes. One
mL of HPLC-grade ethyl acetate was added, tubes were agitated vigorously on a
Vortex Jr. platform for 1 minute and then centrifuged for 15 minutes at 3500 rpm.
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If a plasma volume less than 500 µl of plasma was available for analysis, the
sample was still extracted with 1 mL of ethyl acetate, noting the plasma volume
used. The supernatant was transferred to a clean tube and the extraction
process repeated. The supernatants were combined and dried under nitrogen in
a chemical hood at room temperature. When the solvent had evaporated, tubes
were capped and refrigerated at 4°C until analyzed. The residue was warmed to
room temperature and then reconstituted with a volume of dichloromethane
(Fisher Scientific) equal to the original plasma volume. Tubes were sonicated for
1 minute and the reconstituted extract transferred to numbered sample vials
before placing on the autosampler for analysis.

COTININE
Enzyme Linked Immunoassay (ELISA) kits for cotinine determination were
obtained from Cozart Bioscience, Ltd. (Oxfordshire, UK). Kits included 96-well
plate, standards, wash buffer, enzyme, substrate, and stop solution.
Twenty microliters (µL) of standards (0 to 50 ng/mL) or unknowns (in
duplicate) were added to individual wells coated with anti-cotinine antibody.
Cotinine enzyme conjugate (100 µL) was added to each well and the plate
incubated at room temperature for 30 minutes. Wells were then washed three
times with 350 µL of wash buffer to remove any non-specific plasma
components. One hundred µL of 3,3’,5,5’ tetra methyl benzidine (color reagent)
were added to each well and the samples incubated again at room temperature
for 30 minutes. One hundred µL 3 N HCl were added as a stop solution. Final
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absorbance was measured at 450 nm on a Biotek ELX-800 microplate reader
controlled via Dell Dimension 8100 computer with Windows XP Professional and
Biotek KC4 software. Concentrations of the unknowns were calculated against
the standard curve.

STATISTICAL PLAN AND ANALYSIS
POWER AND SAMPLE SIZE CONSIDERATIONS
There were no preliminary data or published studies available from which
we could extract reliable estimates of the anticipated effect sizes in this study.
Since the primary focus of the statistical analysis for this study will be a
comparison of the PAH and cotinine levels in the matched maternal serum-cord
blood samples, we based our sample size calculation on the value of n required
to achieve 80% power for detecting a small to medium effect size when using the
paired t-test to compare the mean PAH and cotinine levels between the matched
maternal serum and cord blood samples. Using a two-tailed paired t-test with a
significance level of 0.05, a sample size of 60 matched samples would yield 80%
power for detecting a true effect size of 0.35. (177) [Under Cohen’s
classification scheme for effect sizes, 0.2 is considered small and 0.5 is
considered medium.] This sample size of 60 will also yield 80% power for
detecting a true correlation as small as 0.35 between any two analytes (e.g.,
maternal cotinine vs. cord anthracene) using a significance level of 0.05. A
correlation of this magnitude is considered to represent a medium effect size
according to Cohen’s scheme. A total sample size of 60 (corresponding to 30 in
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each of two independent groups) will yield 80% power for detecting a large
sample size (0.80 in Cohen’s scheme) when using the independent samples ttest with a significance level of 0.05. However, independent group comparisons
will not be a major focus of the analyses in this study.
All statistical analyses were conducted with SPSS v.14. Graphs were
produced with Sigma Plot 10.0. Comparison of maternal and matched cord
plasma samples was conducted with paired T-tests. Sub-group comparisons
were conducted with the independent t-test. Logarithmic transformations were
applied prior to examining associations between maternal serum and cord blood
concentrations to improve interpretability of scatterplots. Spearman correlations
were used to measure associations between maternal and cord blood
concentrations. Statistical significance was set at p<0.05.
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RESULTS
Eighty-nine paired specimens were acquired from labor and delivery for this
cross-sectional study. Of those, 25 had incomplete data, lacking either birth
weight, gestational age or both. Sixty-four specimens were considered complete
and included in the study. Infants with birth weight <2.5 kg were considered low
birth weight (LBW). The proportions of LBW infants (12.5%) in this study sample
exceeded the expected Kentucky rate (~8%) by 60%. Infants born before 38
completed weeks’ gestation were considered to be preterm (PT); those
completing 38 or more weeks were considered term (T). The proportion of PT
infants (27.7%) in this sample exceeded the expected rate (~12%) by over 200%.
No infants were considered to be post-term (>42 weeks). Among term infants,
one was large for gestational age (>90th percentile) and 2 were small for
gestational age (<10th percentile). None of the preterm infants demonstrated
aberrant fetal growth. Table 4 describes the specimen pool.
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Table 4.
Demographics of maternal-infant pairs. (Mean, 95% C.I.)
All

Term

Preterm

64 (100%)

46 (72%)

18 (28%)

3.08

3.22

2.07

(2.92, 3.23)

(3.09, 3.34)

(1.67, 2.47)

Gestational

38.1

38.5

35.6

Age (weeks)

(37.6, 38.6)

(38.1, 38.8)

(32.5, 38.6)

8 (12.5%)

3 (6.5%)

5 (27.7%)

N
Birth Weight
(kg)

Low Birth
Weight (<2.5 kg)

The mean cotinine concentration in maternal plasma (47.5 ± 17.2 ng/mL)
was strongly suggestive of high proportions of smoking women among this
cohort. There were no statistically significant differences in concentrations of
anthracene, 1-hydroxypyrene or benzo(a)pyrene between maternal and cord
plasma (Table 5).
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Table 5.
Concentrations of anthracene, benzo(a)pyrene, 1-hydroxypyrene and
cotinine in maternal and cord blood plasma. (Mean, 95% C.I.)
Maternal Plasma

Cord Blood Plasma

N=64

N=64

p

7.0

8.7

0.338

(4.2, 9.8)

(5.6, 11.9)

4.9

3.6

(3.3, 6.6)

(2.8, 4.4)

274.2

279.0

(233.4, 315.1)

(242.0, 315.9)

Cotinine

47.5

46.2

(ng/mL)

(43.2, 51.8)

(39.5, 52.8)

Anthracene
(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)

0.174

0.864

0.732

When groups were distinguished by low birth weight (LBW) or not, there
were no significant differences for either maternal or cord plasma concentrations
(See Table 6).
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Table 6.
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and
cotinine by low birth weight status. (Mean, 95% C.I.)
Maternal Plasma
LBW

Not LBW

p

N=8

N=56

p

0.585

11.2

8.4

0.725

(0, 29.3)

(5.4, 11.3)

3.5

3.6

(0.8, 6.2)

(2.7, 4.5)

269.4

280.4

(235.0,

(144.1,

(240.5,

368.4)

323.6)

394.6)

320.3)

Cotinine

47.7

47.5

60.6

44.1

(ng/mL)

(28.4, 67.1)

(43.1,

(33.6,

(37.2,

51.9)

87.5)

51.0)

ANTH*
(pmol/mL)
BP**
(pmol/mL)
1-HP#
(pmol/mL)

LBW

Not LBW

N=8

N=56

4.9

7.3

(0, 14.4)

(4.3, 10.3)

3.5

5.2

(2.0, 4.9)

(3.2, 7.1)

238.8

279.3

(109.3,

Cord Plasma

0.139

0.510

0.975
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0.951

0.850

0.202

The mean concentration of anthracene in term cord plasma was
significantly higher than in maternal plasma (Table 7). There was no significant
difference in concentrations of anthracene in plasma from mothers and infants
that delivered preterm. Concentrations of cotinine, benzo(a)pyrene and 1hydroxypyrene were similar in maternal and cord plasma, regardless of the
length of pregnancy.

42

Table 7.
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and
cotinine in maternal and cord blood plasma by term or preterm delivery.
(Mean, 95% C.I.)

ANTH*
(pmol/mL)

Term

Preterm

N=46

N=18

Maternal

Cord

p

Maternal

Cord

p

7.8

9.4

0.029

4.8

6.9

0.975

(4.2, 11.5)

(5.5, 13.3)

(1.0, 8.5)

(1.2,
12.7)

BP**
(pmol/mL)

5.5

3.9

0.372

(3.2, 7.8)

(2.8, 5.1)

3.5

2.7

(3.2, 7.8)

(2.8,

0.486

5.1)
1-HP#

246.1

296.0

(239.9,

(188.1,

(185.8,

338.3)

304.8)

304.1)

406.1)

Cotinine

47.7

44.1

46.9

51.3

(ng/mL)

(43.0, 52.4)

(36.3,

(36.6,

(37.4,

51.9)

57.3)

65.3)

(pmol/mL)

285.3

272.4

(232.3,

0.981

0.675
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0.938

0.393

When comparing women who delivered preterm and those delivering at
term (Table 8), all maternal plasma PAH values from women that delivered PT
trended to be lower than those from women that delivered at term, but there were
no significant differences. The mean cord plasma concentration of
benzo(a)pyrene from infants who delivered prior to 38 weeks was significantly
lower than that from infants delivered at term.
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Table 8.
Concentrations of anthracene,* benzo(a)pyrene,** 1-hydroxypyrene# and
cotinine by term or preterm delivery. (Mean, 95% C.I.)
Maternal

ANTH*
(pmol/mL)
BP**

Cord

Term

Preterm

p

Term

Preterm

p

7.8

4.8

0.232

9.4

6.9

0.461

(4.2, 11.5)

(1.0, 8.5)

5.5

3.5

(3.2, 7.8)

(2.5, 4.6)

285.3

246.1

(232.3,

(5.5, 13.3) (1.2, 12.7)
3.9

2.7

(2.8, 5.1)

(2.2, 3.2)

272.4

296.0

(188.1,

(239.9,

(185.8,

338.3)

304.1)

304.8)

406.1)

Cotinine

47.7

46.9

44.1

51.3

(ng/mL)

(43.0, 52.4)

(36.6,

(36.3,

(37.4,

57.3)

51.9)

65.3)

(pmol/mL)
1-HP#
(pmol/mL)

0.120

0.309

0.888
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0.046

0.670

0.355

Visual inspection of the PAH and cotinine data suggested severe
skewness, with several extreme values, so a logarithmic transformation was
applied to each analyte. Figures 7-10 are scatter plots showing the least squares
regression of the log transformed concentrations of cord plasma PAH and
cotinine on the corresponding maternal analytes. LN anthracene: maternal vs.
cord plasma shows a significant positive trend of increasing cord concentrations.
LN benzo(a)pyrene: maternal vs. cord plasma shows a downward trend but the
linear regression is not statistically significant. The graphical representation of LN
1-hydroxypyrene: maternal vs. cord shows a slight downward trend but with
several extreme observations and the regression line for LN cotinine: maternal
vs. cord shows a slight positive trend but, again, there is a wide distribution of
values. Neither of the latter two linear regressions are statistically significant.
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Figure 7.
Scatter plot with linear regression of LN anthracene: maternal vs. cord
plasma
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Figure 8.
Scatter plot with linear regression of LN benzo(a)pyrene: maternal vs. cord
plasma
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Figure 9.
Scatter plot with linear regression of LN 1-hydroxypyrene: maternal vs.
cord plasma
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Figure 10.
Scatter plot with linear regression of LN cotinine: maternal vs. cord plasma
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Given the lack of linear association between log-transformed maternal and
cord plasma concentrations and the presence of so many extreme values,
Spearman correlations were used to measure the associations between maternal
and cord plasma concentrations. There were no significant correlations between
LN benzo(a)pyrene: cord and any maternal PAH or cotinine, or between LN
cotinine: cord and any maternal analyte. None of the data are shown. Tables 910 list the remaining Spearman correlations. Anthracene: cord was significantly
correlated with anthracene: maternal and cotinine: maternal (Table 9). 1hydroxypyrene: cord was significantly correlated with 1-hydroxypyrene: maternal
(Table 10).
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Table 9.
Spearman correlations between maternal concentrations of anthracene,
benzo(a)pyrene, 1-hydroxypyrene, cotinine and cord plasma anthracene.
Cord Plasma Anthracene
(pmol/mL)
Maternal
Anthracene

rs

p

0.38

0.002

-0.09

0.507

0.13

0.302

0.40

0.001

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)
Cotinine
(ng/mL)
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Table 10.
Spearman correlations between maternal concentrations of anthracene,
benzo(a)pyrene, 1-hydroxypyrene and cotinine and cord plasma 1hydroxypyrene.
Cord Plasma 1-hydroxypyrene
(pmol/mL)
Maternal
Anthracene

rs

p

0.01

0.965

0.11

0.399

0.25

0.043

-0.13

0.323

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)
Cotinine
(ng/mL)
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Plasma cotinine concentrations were individually subjected to Spearman
correlation analysis with each PAH compound separately for the maternal and
cord concentrations. In maternal plasma, cotinine was positively correlated with
1-hydroxypyrene (Table 11). In cord plasma, cotinine was negatively correlated
with 1-hydroxypyrene as seen in Table 12.
Table 11.
Correlations between maternal plasma concentrations of cotinine and
individual PAH

MATERNAL COTININE

Anthracene

rs

p

0.09

0.487

-0.05

0.690

0.30

0.016

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)
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Table 12.
Correlations between cord plasma concentrations of cotinine and
individual PAH

CORD COTININE

Anthracene

rS

p

0.01

0.912

-0.01

0.915

-0.26

0.038

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)
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Maternal plasma PAH compounds correlated significantly with each other
(Table 13). However there was no correlation between maternal cotinine and the
individual PAH (data not shown).
Table 13.
Correlations among maternal plasma PAH and cotinine
MATERNAL
Benzo(a)pyrene

Anthracene

1-Hydroxypyrene

rS

p

rS

P

0.32

0.011

0.32

0.009

0.28

0.025

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
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Unlike what was seen in the maternal plasma, cord plasma PAH
compounds did not show significant correlations. However, cotinine: cord did
correlate significantly with 1-hydroxypyrene. (Table 14).
Table 14.
Correlations among cord plasma PAH and cotinine.
CORD
Benzo(a)pyrene

Anthracene

1-Hydroxypyrene

Cotinine

rS

p

rS

p

rS

p

0.08

0.518

0.03

0.814

0.14

0.912

0.23

0.065

-0.01

0.915

-0.26

0.038

(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)
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After reviewing studies from Jauniaux (178) Ziegler (179) and Perera (3),
a maternal cotinine concentration of 35 ng/mL was chosen as a cut-point to
distinguish between two groups of women: those whose tobacco smoke
exposure was limited (none-light) and those whose smoke exposure was more
significant (moderate-heavy). Differences in maternal PAH concentrations within
those sub-groups are shown in Table 15. The concentration of anthracene in the
moderate-heavy group was more than twice that of the none-light group and was
statistically significant; the other PAH were not.
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Table 15.
Maternal anthracene, benzo(a)pyrene and 1-hydroxypyrene by maternal
cotinine subgoups (Mean, 95% C.I.)

Anthracene
(pmol/mL)
Benzo(a)pyrene
(pmol/mL)
1-Hydroxypyrene
(pmol/mL)

Maternal cotinine

Maternal cotinine

<35 ng/mL

≥35 ng/mL

N=8

N=56

3.0

7.6

(0.6, 5.4)

(4.4, 10.7)

3.3

5.2

(1.9, 4.7)

(3.3, 7.1)

232.7

280.2

(154.0, 311.4)

(234.4, 326.0)

p

0.019

0.105

0.259

When birth weight, gestational age and cord plasma concentrations of
PAH and cotinine were compared in the two maternal smoking groups, mean
anthracene remained significantly higher in the moderate-heavy smoking group
(Table 16). Cord plasma benzo(a)pyrene was lower in the none-light group, but
did not reach statistical significance. There was no statistically significant
difference in concentrations of 1-hydroxypyrene between the groups.
Interestingly, cord plasma cotinine was similar between the groups (43.0±24.7
vs. 46.6±27.3 ng/mL, none-light compared to moderate-heavy, respectively)
despite an almost 2-fold difference in the maternal cotinine concentrations
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(27.2±7.7 vs. 50.5±16.2 ng/mL, none-light compared to moderate-heavy,
respectively).
Table 16.
Birth weight, gestational age, cord plasma PAH and cotinine by maternal
cotinine subgroups (mean, 95% C.I.)
Maternal cotinine

Maternal cotinine

<35 ng/mL

≥35 ng/mL

N=8

N=56

2.94

3.09

(2.4, 3.5)

(2.9, 3.3)

36.9

38.3

(35.0, 38.8)

(37.7, 38.8)

4.2

9.4

(1.0, 7.4)

(5.8, 12.9)

2.7

3.7

(2.3, 3.2)

(2.8, 4.7)

262.9

281.3

(156.8, 369.0)

(240.7, 321.9)

Cotinine

43.0

46.6

(ng/mL)

(22.3, 63.7)

(39.3, 53.9)

BW (kg)

GA (wks)

ANTH*
(pmol/mL)
BP**
(pmol/mL)
1-HP#
(pmol/mL)

*Anthracene
**Benzo(a)pyrene
#

1-Hydroxypyrene
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p

0.533

0.151

0.026

0.061

0.717

0.713

To summarize the results of this study, there were significant correlations
between:
•

Maternal and cord concentrations of anthracene,

•

Maternal and cord concentrations of 1-hydroxypyrene,

•

Anthracene, benzo(a)pyrene and 1-hydroxypyrene in maternal plasma,

•

Maternal cotinine and cord anthracene,

•

Maternal cotinine and cord 1-hydroxypyrene,

•

Cord cotinine and cord 1-hydroxypyrene.

There were significant differences between:
•

Cord concentrations of benzo(a)pyrene in term vs. preterm

•

Cord concentrations of anthracene in subgroups based on maternal
cotinine above or below 35 ng/mL

•

Cord concentrations of anthracene in subgroups of maternal low,
moderate and heavy smoking prior to delivery
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DISCUSSION
Smoking during pregnancy remains a significant public health concern
despite considerable evidence of the dangers in scientific literature and lay press.
The physical evidence for maternal harm from smoking during pregnancy has
been known for decades and has been discussed earlier in this paper:
•

Miscarriage/spontaneous abortion

•

Placenta previa, placental abruption

•

Preterm delivery

Infant effects, both immediate and in the months after birth, are also well known
and have been discussed:
•

Low birth weight (even after a full term gestation)

•

Nicotine withdrawal during the first hours after birth

•

Decreased arousability from sleep

•

Increased risk for sudden infant death syndrome (SIDS)

The data related to learning delays and behavioral disturbances are less clear
because of the confounding effects of social and genetic factors. However,
concerns remain because of data from animal studies that show the disruptive
effects of nicotine on neural development.
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This study began with 4 research questions.
1. Are anthracene, benzo(a)pyrene and 1-hydroxypyrene present in
measurable concentrations in maternal and cord blood plasma?
Yes. Each PAH was measured in both maternal and cord blood plasma,
although in some individuals, the concentrations were very low.
2. Do plasma concentrations of anthracene, benzo(a)pyrene and/or 1hydroxypyrene correlate with cotinine among smoking and non-smoking
women?
Maternal cotinine was correlated only with 1-hydroxypyrene in maternal plasma.
Maternal cotinine did, however, correlate significantly with cord anthracene and
1-hydroxypyrene. Within cord plasma samples, as was seen in maternal plasma,
cotinine was correlated only with 1-hydroxypyrene.
3. Do plasma concentrations of anthracene, benzo(a)pyrene and 1hydroxypyrene in cord blood parallel levels in maternal plasma?
Again, the answer is no. Extremes of concentrations existed within paired
maternal and cord plasma samples in which very high concentrations in maternal
plasma were coupled with low concentrations in cord plasma and vice versa.
Mean anthracene concentrations always trended to be higher in cord plasma
than in maternal plasma regardless of the subgroup being studied (term, preterm,
low birth weight), but without reaching statistical significance. This suggests that
there may either be a concentrating effect on the fetal side, as has been
observed with nicotine (138), or that the fetus lacks the enzyme machinery to
metabolize anthracene to other compounds, perhaps leading to an accumulation

63

over time. The effect of labor, especially its duration, on the processes involved
in PAH and cotinine metabolism are not known.
Benzo(a)pyrene trended to be higher in maternal plasma than in cord
while 1-hydroxypyrene was not consistently higher or lower in one or the other
even though it did correlate with maternal and cord cotinine.
4. Are plasma concentrations of anthracene, benzo(a)pyrene and 1hydroxypyrene correlated with birth weight or gestational age?
Although our sample had more low birth weight and preterm infants than would
be expected, it did not appear that concentrations of any of the measured PAH or
cotinine were correlated with those outcomes. This study has shown, however,
that anthracene, benzo(a)pyrene and 1-hydroxypyrene are present in cord blood
in measurable concentrations.
Given the thousands of chemicals found in tobacco smoke, it is difficult to
attribute any one effect to a single chemical or group of chemicals. Much
research has focused on nicotine and carbon monoxide and the resulting hypoxia
and vasoconstriction that are believed to be responsible for intrauterine growth
restriction and low birth weight (95, 122, 139, 180, 181). Other recent studies
have linked components of tobacco smoke, especially PAH, to a variety of
enzymatic, inflammatory and cellular changes in the placenta and the fetus. (43,
182-190)
Unlike a singular event that may or may not coincide with a critical epoch,
maternal smoking during pregnancy represents chronic exposure of the fetus to
the thousands of compounds in tobacco smoke many times a day over multiple
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days or weeks. Repeated exposure across numerous critical windows may
amplify the resulting effect from very early in gestation. Although it is impossible
to know how many fetal organs, cells, organelles and genes are altered each
time a woman smokes a cigarette, it clear that these compounds are reaching
the fetus in measurable quantities.
Kentuckians are caught in a vortex of poor health: excessive and
increasing numbers of low birth weight and preterm infants, rising numbers of
overweight/obese children and adults with many dying from heart-related
disease. A large proportion of these problems can be attributed to the “Kentucky
3-point lifestyle:”
•

Cigarettes

•

Junk food

•

Inactivity

If programming theory is correct, we face an even more difficult task to break out
of that cycle given the numbers of infants that experience sub-optimal gestational
conditions which are then reinforced by the Kentucky life style. The
unacceptably high numbers of infants that experience the ill effects of their
mothers’ smoking before and after birth are but one facet of the two-pronged
public health challenge before us: 1) to convince children and adolescents to
avoid smoking at all and 2) to encourage and support smokers in their efforts to
quit. This second task is especially important for women who are or who are
thinking about becoming pregnant.
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LIMITATIONS OF THE STUDY
There were several limitations in this study.
1. This was a pilot study, and as such, was designed to gather
preliminary data for a larger study rather than to test a specific
hypothesis. There are over 4,000 chemicals in tobacco smoke; this
study only attempted to study 3. There are many more that remain
unstudied.
2. Maternal blood specimens were drawn at the time of admission to the
labor and delivery service in order to avoid an extra blood draw for the
mother. Thus, there was a time lapse between the maternal specimen
and the cord blood specimen drawn at delivery. While cotinine has a
half-life of 18-20 hours, the time difference between specimens is a
variable that was not quantified.
The prevalence of high concentrations of cotinine suggest there
were over 85% moderate to heavy smokers in this convenience
sample, a condition that is highly unlikely. While cotinine is a good
screening method, there are factors that could affect cotinine
concentrations at the time of the blood draw, including the time lapse
since the last cigarette, routine smoking patterns of the women,
plasma volume, the duration and intensity of labor, as well as the level
of environmental exposures other than personal tobacco smoking that
could increase cotinine levels. All of these items are unknowns due to
the anonymity of the blood samples. A better marker of true tobacco
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smoke exposure would be hemoglobin-protein adducts, such as 4amino-biphenyl. (191) Assays for these adducts were not performed
for this study but will be included in future extensions of this research.
3. These were anonymous samples, lacking data as to the mother’s
smoking history, diet, physical parameters of the pregnancy, etc. This
decision was based on early experience that women smokers were
quite reluctant to participate in a study that was focused on effects of
smoking on the fetus. Ultimately this would lead to a bias toward nonsmokers in the sampled population.
4. While personal smoking is presumed to be the major source of PAH in
this sample, there are no data as to PAH exposure resulting from air
pollution or from the woman’s local environment. A woman’s home or
work environment that provided excessive exposure to air-borne
particulates and/or PAH could have a significant effect on the
concentrations we saw even if she, herself, was not a smoker.

FUTURE RESEARCH
This study suggests several additional investigations. Prospective studies
of women, smokers and non-smokers, that follow them in detail throughout their
pregnancies with periodic blood samples and activity diaries, augmented by
amniotic fluid studies, if warranted by normal clinical care, and delivery studies
(maternal and cord) would create a more complete picture of gestational
exposure and effects in the infant. These studies could include genotyping for
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enzyme polymorphisms and biomarkers of exposure (DNA or hemoglobin protein
adducts) as well as quantitation of a wider panel of PAH.
Monitoring of PAH or levels of other compounds in women that decrease
or actually quit smoking during pregnancy would provide insight into the
persistence of these compounds once smoking is no longer a factor. Postnatal
studies of infants, especially those that experienced growth restriction in-utero,
should focus on early growth recovery (catch-up) and neurodevelopmental
progress. Another approach to combating the in-utero growth restriction could
involve nutritional intervention to promote growth recovery.
The same plasma samples from this study can be further analyzed for
other PAH and their metabolites as well as hemoglobin adducts. Further study of
anthracene and its metabolites/adducts may enhance current investigations.
Body composition studies of infants that do and do not experience in-utero
growth restriction from maternal smoking may be useful in helping to determine
what facet of body growth is constrained by the action of smoking. New
technology makes these studies rapid, non-invasive and reliable.
A study that is underway involves quantitating these compounds in the
milk of women that deliver preterm and correlating the results with growth
outcomes in the nursery. Due to the benefits of human milk for human babies,
breastfeeding will almost always be the preferred method of feeding. However, it
is important to understand the level to which these compounds in mother’s milk
may add to an infant’s in- utero body burden.
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These and many other studies will continue as tobacco smoking and air
pollution are here to stay. Basic science investigators will continue to use
improving technology to focus on the why and how tobacco impacts human
health. Public health professionals will continue to educate policy makers and
the general public to the importance of eliminating tobacco smoke from the
environment for the good of everyone, but especially infants and children.
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